Table S1-5 from Target Deconvolution of a Multikinase Inhibitor with Antimetastatic Properties Identifies TAOK3 as a Key Contributor to a Cancer Stem Cell–Like Phenotype

Suppl. Table 1. Origin of cancer cell lines used in this study. Suppl. Table 2. Quantitative HTS screen in PANC1 cells grown as spheroids. Results of full ten concentration drug-response curves of 1,912 individual agents and compounds in PANC1 spheroids. SID, Sample ID; CCLASS, Curve class; CCLASS2, Curve class (latest version); LAC50, log AC50 (M); HILL, Hill coefficient; ZERO, fitted response at minimum concentration; INF, Fitted response at maximum concentration; MAXR, Observed response at maximum concentration; DATA0 - DATA10, Responses; C0 - C10, Doses (in µM); auc, Area Under the Curve (via integration of the fit). This data is available via the PubChem database (AID 1259363). Suppl. Table 3 Top twenty hits of KiNativ profiling of PANC1 cells with at least {greater than or equal to}50 percent inhibition of ADP binding following treatment with 500 nM of inhibitor #1. Suppl. Table 4. In vitro activity of inhibitor #1 against a panel of over 400 kinases (DiscoveRx's KinomeScan) and in situ activity of inhibitor #1 in PANC1 spheroid cells (KiNative). Suppl. Table 5. Outcomes of both 6Ã-6 and 10Ã-10 combination drug screening of inhibitor #1 versus a collection of approved and investigational drugs.